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In the present study, four different diamine ligands I-IV were studied in coordination with an iridium metal complex 
with the biotin moiety anchored to the Cp*ring. This strategy, in contrast to the traditional biotin-streptavidin 
technology based on the use of a biotinylated ligand in the resulted artificial imine reductase, outcome particularly 
practical for envisaging how the enantiodiscrimination operated by different Sav mutants could influence the chiral 
environment of the metal cofactor. Only in the case of (R)-CAMPY IV the chirality at the metal centre and the second 
coordination sphere environment, dictated by the host protein, resulted to operate in a synergistic way, thus 
leading to a better enantioselectivity when the S112M Sav catalyst/ catalyst ratio was settled at 1.0:2.5. Under 
these optimized conditions the artificial imine reductase afforded a valuable enantiomeric excess (83 %) in the ATH 
of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline.
Introduction 
Enantioselective catalysis provides an efficient and versatile tool for the synthesis of many biologically active 
compounds in which chirality plays a critical role such as pharmaceuticals and agrochemicals.1, 2 In this regard both 
transition metal catalysis and biocatalysis have been the catalytic approaches more deeply exploited to produce 
enantiopure products. These synthetic methods have been considered as separated fields until recently when the 
so-called artificial metalloenzymes (Ar-Ms) have risen as a promising approach able to merge the attractive 
properties of the two worlds.3, 4 Ar-Ms are hybrid catalysts in which a transition metal complex is embedded within 
a biological environment. The idea is to join the broad scope of organic transformations catalysed by metal catalysts 
to the exquisite selectivity exhibited by enzymes.5-9 In the case of a conventional transition metal catalyst, the 
selectivity of the reaction relies totally on the first coordination sphere determined by the nature and the 
stereochemistry of the ligands around the metal centre. In this context, chiral phosphines and diamine ligands 
endowed with different steric and electronic properties have been extensively investigated for enhancing the 
performances of such a type of homogenous catalysis.10-15 
Conversely, in the enzymatic catalysis the intricate network of interactions within the biological scaffold creates a 
chiral second coordination sphere environment around the catalytic site responsible for the high levels of enantio-
discrimination as well as for the reduction in the energy barriers of the catalysed transformation thus resulting in 
extreme enantioselectivity along with accelerated reaction rates.16 In the of Ar-Ms, by incorporating an 
organometallic compound within a three dimensionally defined biological structure it is possible to synthesise a 
transition metal catalyst exhibiting the above-mentioned enzyme features.17-22 
In the context of the Ar-Ms based on the biotin-streptavidin technology our research group recently developed an 
artificial imine reductase in which a chiral biotinylated 1,3 diamine ligand in coordination with an iridium (III) centre 
was anchored to a streptavidin mutant and employed in the stereoselective reduction of the salsolidine 
precursor.23 In that study the use of such a poorly investigated type of diamine ligands shed light on those protein 
residues that more deeply affected the stereoselectivity of the reaction. In the present work to expand the artificial 
cofactor library, a chemical optimization of the imine reductase was performed by exploring how a series of diamine 
ligands different in structure and electronic properties would impact on the ability of the second coordination 
sphere to induce selectivity in the asymmetric transfer hydrogenation of the model substrate. Indeed, we reasoned 
that this goal would be more easily appreciated by tethering the biotin anchor to the Cp* moiety so that the 
reactivity of the first coordination sphere would be exclusively dictated by the features of the chelating amines 
around the iridium centre. 
Results and discussion 
 
 
Starting from the pioneering work by Ward,24-26 in the present work the chemical optimization strategy was 
applied to the synthesis of the biotinylated catalyst precursor [IrCp*biotinCl2]2 then reacted in situ with different 
bidentate ligands to be employed in the preparation of the artificial metalloenzymes. In particular, we focused our 
attention on the use of a series of diamine chelating ligands different for both steric and electronic features: two 
achiral diamines based on imidazole moiety previously investigated by our group in platinum(II) complexes as 
anticancer agents,27 i.e. the (1-methyl-1H-imidazol-4-yl)methylamine I and the (1-methyl-1H-imidazol-2-
yl)methanamine II, a chiral 1,3 diamine III23 already applied to the synthesis of Ar-Ms and the 8-Amino-5,6,7,8-
tetrahydroquinoline, called CAMPY IV,28, 29 recently revealed an efficient chiral ligand in iridium complexes for the 
ATH of cyclic imines .30 (Scheme 1) 
 
Scheme 1. Artificial imine reductases based on different selection of diamine ligands 
A preliminary screening was performed in the ATH of the chosen substrate in the presence of achiral imidazole 
ligands I and II using different Sav mutants either bearing a single mutated residue at position S112 or K121 or with 
a double mutation at position S112 or K121 in addition to a mutation at residue L124. 31 (Table 1) 
The choice of the positions of mutagenesis in aminoacids position was applied in function of estimated proximity 
to the catalytic metal determined by Ward and co-workers through x-ray crystal structure of the most selective 
studied ATHase reductase.32 
Moreover, knowing the sensitivity of the catalytic performance of such hybrid systems to many experimental 
parameters, different reaction conditions were evaluated: activation time, reaction temperature, substrate 
concentration and substrate/catalyst ratio (data not reported). 
As a general trend emerged from the data reported in Table 1, in the presence of I and II a racemic mixture of the 
product was generally obtained. Only using in the case of Sav mutants S112A, S112T and S112Y+K121R the imine 
reductase bearing diamine II in its first coordination sphere was able to afford a really modest enantiomeric excess 
(up to 13 %). A significant effect deserving to be noted was the inversion of the configuration of the reaction product 
in function of the Sav mutant. (Table 1, entries 8, 10 and 19) 
With the aim to study how the chirality of the diamine could improve the catalytic system in which the biotinylated 
piano stool complex represents the anchor factor to Sav-WT and Sav mutants, we decided to introduce in the first 
coordination sphere two chiral diamines, III and IV. (Table 2) 
The results obtained with the chiral 1,3-diamine III, in which the coordination to the metal centre led to the 
formation of a labile six membered ring, confirmed the poor selectivity induced in the product formation. In this 
case, only in the presence of K121H and K121A mutants, a modest enantiomeric excess was achieved. (Table 2, 
entries 15 and 17) 
Table 1. Screening of chemogenetic optimization of ATHases for asymmetric reduction of the salsolidine precursor 
with diamine I and II. 
 
 
 
 
ENTRY SAV I[A] II[A] 
1 no 99 (rac) 99 (rac) 
2 WT 8 (rac) 17 (6 S) 
3 S112Q 45 (rac) 99 (rac) 
4 S112R 57 (rac) 99 (3 S) 
5 S112M 43 (4 R) 99 (rac) 
6 S112C 5 (rac) 5 (rac) 
7 S112H 49 (rac) 99 (rac) 
8 S112A 59 (rac) 99 (10) 
9 S112E 52 (rac) 99 (rac) 
10 S112T 43 (rac) 94 (9 R) 
11 S112Y 53 (5 R) 99 (rac) 
12 S112K 66 (rac) 99 (rac) 
13 S112W 68 (8 R) 99 (5 S) 
14 K121R 55 (rac) 99 (6 S) 
15 K121H 19 (rac) 99 (rac) 
16 K121F 99 (4 R) 99 (5 S) 
17 K121A 73 (rac) 99 (rac) 
18 K121M 73 (3 R) 99 (3 S) 
19 S112Y+K121R 83 (rac) 99 (13 
R) 
20 S112K+L124E 69 (rac) 99 (rac) 
21 S112C+K121H 6 (rac) 9 (7 S) 
Reaction condition:  substrate 19 mM, 1 mol % ligand, 0.45 mol % [IrCp*biotinCl2]2, 4 mg/mL mutant Sav, MOPS 
0.6 M pH 7.8, HCOONa 3 M, 18 h at 30°C. [a] conversion (e.e.%). 
In the case of the 1,2 diamine CAMPY IV as ligand, better results in terms of enantioselectivity were obtained. 
Considering the good ability of CAMPY to induce in chirality of the corresponding metal complexes and the 
possibility to influence their catalytic activities depending on the selected Sav mutant, both the enantiomers of 
ligand IV were evaluated. Some considerations occurred: 
In the presence of all the mutants the conversion of the reaction to the product resulted decreased (up to 77 % for 
(S)-IV in presence of S112K Sav mutant, table 2, entry 12). 
 
 
The (S)-IV ligand gave always the S enantiomer of the product while the (R)-IV gave always the R enantiomer for all 
the Sav mutants, confirming that the enantiopure environment provided by the host Sav resulted to influence the 
chirality of the product at a less extent. 
In all cases the enantioselectivity resulted equal or decreased in presence of Sav, demonstrating that because of 
the rigid backbone of the CAMPY ligand the corresponding metal co-factor was probably not sufficiently embedded 
within the host protein for steric reasons. 
Table 2. Screening of chemogenetic optimization of ATHases for asymmetric reduction of the salsolidine precursor 
with diamine (S)-III, (S)-IV and (R)-IV. 
ENTRY SAV (S)-III[A] (S)-IV[A]  (R)-IV[A] 
1 no 91 (3 R) 99 (59 S) 99 (65 R) 
2 WT 39 (7 R) 8 (57 S) 12 (43 R) 
3 S112Q 99 (rac) 42 (32 S) 30 (42 R) 
4 S112R 99 (9 R) 32 (31 S) 32 (41 R) 
5 S112M 85 (6 R) 35 (41 S) 27 (68 R) 
6 S112C 20 (7 R) 9 (31 S) 5 (8 R) 
7 S112H 52 (6 R) 25 (41 S) 17 (32 R) 
8 S112A 94 (7 R) 35 (32 S) 45 (46 R) 
9 S112E 91 (rac) 38 (30 S) 35 (43 R) 
10 S112T 64 (rac) 27 (40 S) 25 (51 R) 
11 S112Y 91 (rac) 39 (28 S) 19 (49 R) 
12 S112K 87 (6 R) 77 (29 S) 27 (41 R) 
13 S112W 49 (rac) 31 (39 S) 45 (45 R) 
14 K121R 51 (rac) 34 (37 S) 33 (54 R) 
15 K121H 44 (12 R) 22 (41 S) 28 (48 R) 
16 K121F 88 (rac) 49 (38 S) 35 (36 R) 
17 K121A 99 (13 R) 42 (29 S) 35 (34 R) 
18 K121M 57 (5 R) 13 (54 S) 27 (54 R) 
19 S112Y+K121R 99 (5 R) 34 (12 S) 45 (41 R) 
20 S112K+L124E 64 (4 R) 59 (47 S) 32 (50 R) 
21 S112C+K121H 21 (rac) 7 (40 S) 10 (25 R) 
Reaction conditions:  substrate 19 mM, 1 mol % ligand, 0.45 mol % [IrCp*biotinCl2]2, 4 mg/mL mutant Sav, MOPS 
0.6 M pH 7.8, HCOONa 3 M, 18 h at 30°C. [a] conversion % (e.e.%). 
Considering that the best results in terms of enantioselectivity for both the enantiomers of diamine IV were 
obtained in presence of S112M Sav mutant, other than the above-mentioned reaction conditions influencing the 
reactivity and the selectivity of the system were evaluated: different buffers at different pH and the S112M Sav 
mutant/ligand ratio. This last aspect was changed taking into consideration the tetrameric structure of Sav-WT, 
known for existing as a dimer of dimers each one providing a biotin binding site.33 
The results are summarized in Table 3. 
Table 3. Optimized results obtained using diamine IV and S112M Sav mutant. 
ENTRY BUFFER S112M/LIGAND  
RATIO 
(R)-IV[B] 
1  acetate pH 5[a] 1.0:1.5 7 (53 R) 
2 MES pH 6[a] 1.0:1.5 13 (60 R) 
3 phosphate pH 8[a] 1.0:1.5 7 (17 R) 
4 MES pH 7[a] 1.0:1.5 14 (59 R) 
5  MOPS pH 7.8 1.0:1.0 23 (62 R) 
6  MOPS pH 7.8[a] 1.0:1.5 27 (68 R) 
7  MOPS pH 7.8 1.0:2.5 32 (83 R) 
Reaction conditions:  substrate 19 mM, 1 mol % ligand, 0.45 mol % 6[IrCp*biotinCl2]2, MOPS 0.6 M pH 7.8, 
HCOONa 3 M, 18 h at 30°C. [a] 4 mg/mL S112M Sav [b] conversion % (e.e. %).  
From the results summarised in Table 3 using diamine(R)-IV, the following considerations could be made: 
Taking into consideration the enantioselectivity but also the reactivity afforded by the system, MOPS buffer at pH 
7.8 turned out as the best reaction medium compared to MES at pH 6 and pH 7. (Table 3, entry 6 vs entries 2 and 
4) 
When the Sav mutant/metal cofactor ratio was changed, the enantiomeric excess of the product showed a 
significant variation. In fact, bearing the ratio to 1.0:2.5, the enantioselectivity increased up to a significant 83 % 
e.e.  along with a modest increase also in the reactivity (32 % yield). (Table 3, entry 7). 
The observed changes in the enantioselectivity of the imine reductase activity as a consequence of a  different 
Sav/metal cofactor ratio seems to fit the observation made above that because of the rigid structure of CAMPY 
ligand the metal cofactor probably fully occupied only one active site of the Sav, underlining that the steric 
hindrance played an important role in stabilizing a specific second coordination sphere environment thus dictating 
which prochiral face of the substrate can approach the hydride to afford the preferred enantiomer of the product. 
Under these conditions in fact, when two (R)-(R)-metal cofactors occupied simultaneously two close-lying biotin 
binding sites (the first in a dimer and the second in the opposite dimer of the tetrameric streptavidin for minimizing 
clashes between the two cofactors) each monomer is active and might behave independently with no interaction 
between the adjacent cofactors that allowed to increase the e.e. to an appreciable 83% in the case of S112M Sav 
mutant. 
Experimental 
General. Diamine I and II were purchased by Merck. The synthesis of diamine III and IV proceeded as reported in 
literature.11, 28 The synthesis of [IrCp*biotinCl2]2 was performed according to the literature.31, 34, 35 Catalytic 
reactions were monitored by HPLC analysis with Merck-Hitachi L-7100 equipped with Detector UV6000LP and chiral 
column (OD-H Chiralcel).  
General procedure for asymmetric transfer hydrogenation. 
[IrCp*biotinCl2]2 (1.9x10-5 mmol) and ligand (3.95x10-5 mmol) was dissolved in 100 µL of MOPS buffer 0.6 M pH 
7.8 and stirred for 30 min at 30°C. The corresponding lyophilized Sav mutant (0.8 mg) was added and the mixture 
was agitated to ensure the binding between the precomplexed biotinylated metal system and the Sav. The 
substrate (final concentration 19 mM) was dissolved in 100 µl of buffer (HCOONa 6 M, MOPS 0.6 M, final pH 7.8) 
and added to the catalyst solution. The reaction was stirred for 18 h at 30°C. At the end of the reaction 10 µL of 
NaOH 10 N was added and the aqueous media was extracted with CH2Cl2. The organic layers were dried with 
anhydrous Na2SO4, filtered and the solvent was removed under vacuum for been analysed by HPLC equipped with 
chiral column. (eluent hexane/ethanol/DEA=95/5/0.1; λ=283 nm; flow=1.0 mL/min; retention time for starting 
material 10.9 min; enantiomers of the product: tS=17.2 min; tR=21.3 min) 
Conclusions 
In conclusion, the biotinylated piano stool complexes revealed to be a labile catalytic system with all the Sav 
mutants unless in the presence of chiral chelating ligand able to stabilise one enantiomer at the biotinylated 
Cp*metal precatalyst if compared to the conventional biotin-streptavidin technology in which the enantioselection 
 
 
occurred also with an achiral biotinylated ligand. The difference between the rigid 1,2 diamine ligand IV and a 
flexible ligand as the 1,3 diamine III, despite both chiral, confirmed the importance of a five membered coordination 
ring at the metal centre also in presence of a structural different artificial metalloenzyme. Under optimized 
conditions (MOPS pH 7.8, Sav mutant/ligand ratio 1.0:2.5), the imine reductase formed by (R)-CAMPY bound to 
S112M Sav mutant showed an appreciable enantioselectivity in the ATH of the 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline (up to 83% e.e.).  
Considering the wide versatility offered by this new approach in designing artificial metalloenzymes, in the future 
different ligands and metal complexes opportunely modified, i.e. in the spacer length and nature between the 
biotin anchor and the Cp* ring, could be investigated and optimized to improve the scope of the reaction.  
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